| Mary Beth Chrestman, LCSW | |
|
1315 Jefferson Hwy, New Orleans, LA 70121-2406 | |
| (504) 842-3900 | |
| Not Available |
| Full Name | Mary Beth Chrestman |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 1315 Jefferson Hwy, New Orleans, Louisiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356938708 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 12043 (Louisiana) | Primary |
| Entity Name | Ochsner Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538151428 PECOS PAC ID: 8224933619 Enrollment ID: O20031126000513 |
News Archive
A clinical trial will examine an investigational drug's early bacteria-killing activity in patients newly diagnosed with drug-sensitive pulmonary tuberculosis.
NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has closed a convertible debenture financing in which the convertible debentures are convertible under specified circumstances into existing class B preferred shares for a total of approximately $14 million.
ProNAi Therapeutics, Inc., a leader in developing nucleic acid therapeutics, presented safety and efficacy data from its ongoing Phase II study yesterday at the 55th Annual Meeting of the American Society for Hematology (ASH) in New Orleans, Louisiana.
GTx, Inc. (Nasdaq: GTXI) today reported financial results for the second quarter of 2009. The net loss for the second quarter and six months ended June 30, 2009 was $11.3 million and $22.6 million, respectively, compared with a net loss of $13.2 million and $26.0 million for the same periods in 2008. At June 30, 2009 GTx had cash, cash equivalents and short-term investments of $68.9 million.
Competitive Technologies, Inc. announced today that the Department of Veterans Affairs' Federal Supply Schedule Service has accepted CTT's application to be an approved vendor for its Calmare® Pain Therapy Treatment. This decision will enable CTT to sell Calmare Pain Therapy to physicians throughout the Federal government, with the expectation of significant sales in that market sector, which includes the Department of Veterans Affairs, the Department of Defense, the Indian Health Service, the Bureau of Prisons, and State Veteran Homes.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mary Beth Chrestman, LCSW 1514 Jefferson Hwy, New Orleans, LA 70121-2429 Ph: (504) 842-4000 | Mary Beth Chrestman, LCSW 1315 Jefferson Hwy, New Orleans, LA 70121-2406 Ph: (504) 842-3900 |
News Archive
A clinical trial will examine an investigational drug's early bacteria-killing activity in patients newly diagnosed with drug-sensitive pulmonary tuberculosis.
NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has closed a convertible debenture financing in which the convertible debentures are convertible under specified circumstances into existing class B preferred shares for a total of approximately $14 million.
ProNAi Therapeutics, Inc., a leader in developing nucleic acid therapeutics, presented safety and efficacy data from its ongoing Phase II study yesterday at the 55th Annual Meeting of the American Society for Hematology (ASH) in New Orleans, Louisiana.
GTx, Inc. (Nasdaq: GTXI) today reported financial results for the second quarter of 2009. The net loss for the second quarter and six months ended June 30, 2009 was $11.3 million and $22.6 million, respectively, compared with a net loss of $13.2 million and $26.0 million for the same periods in 2008. At June 30, 2009 GTx had cash, cash equivalents and short-term investments of $68.9 million.
Competitive Technologies, Inc. announced today that the Department of Veterans Affairs' Federal Supply Schedule Service has accepted CTT's application to be an approved vendor for its Calmare® Pain Therapy Treatment. This decision will enable CTT to sell Calmare Pain Therapy to physicians throughout the Federal government, with the expectation of significant sales in that market sector, which includes the Department of Veterans Affairs, the Department of Defense, the Indian Health Service, the Bureau of Prisons, and State Veteran Homes.
› Verified 5 days ago
Dr. Rebecca Linnea Kendig, PH.D., LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 8620 Jeannette St, New Orleans, LA 70118 Phone: 504-292-1447 | |
Melissa Scheib, CSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 4919 Canal St, Suite 203, New Orleans, LA 70119 Phone: 504-483-9883 | |
Sarah Tebbe, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2640 Canal St Ste 4, New Orleans, LA 70119 Phone: 504-821-2232 | |
Jacqueline Saunders, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 701 Loyola Ave Ste 108, New Orleans, LA 70113 Phone: 504-503-0878 Fax: 504-503-0893 | |
Ms. Monica Marie Mills-mattox, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 1050 S Jeff Davis Pkwy Ste 240, New Orleans, LA 70125 Phone: 832-725-0586 Fax: 888-977-1299 | |
John Maloney, LCSW Clinical Social Worker Medicare: May Accept Medicare Assignments Practice Location: 4316 State Street Dr, New Orleans, LA 70125 Phone: 504-722-7932 Fax: 337-443-2890 | |
Mrs. Shenicka Adams Varnado, LMSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 3801 Canal St, Suite 314, New Orleans, LA 70119 Phone: 504-483-7254 |